ONCA LEUKEMIA CLL (B-CELL) ALEMTUZUMAB - PRL45
Alemtuzumab (3mg) subcutaneous c1d1 then (10 mg) subcutaneous c1d3; then (30 mg) subcutaneous c1d5; then Alemtuzumab (30mg) subcutaneous d1,  3 and 5 (MWF) q7d x 12 (c2-13)

Cycle length = 7 days
 
Provider Reminders
Consider antifungal prophylaxis.
Continue PCP/antiviral prophylaxis for 2 months post therapy or until the CD4+ count is greater than or equal to 200 (whichever is later). 
Patients receiving ALEMTUZUMAB should receive irradiated blood to prevent transfusion-associated graft-versus-host disease (TA-GvHD). Please designate in your orders for blood products. Inform your blood bank, and add to the problem list or other charting field chosen by your region.
Drug supply is through a restricted distribution program from the manufacturer, please consult pharmacist for detail.
 
Lab Orders
Baseline Labs (one time draw, prior to first cycle):
CBC , CMV DNA Quantitative PCR, Uric Acid, Hep BsAg, Hep BcAb
________________________________________________________________________________________________
 
Lab Parameters to Assess:
Cycles 1 through 13, Day 1 (weekly): ANC greater than or equal to 500; Platelets greater than or equal to 50,000
Withhold alemtuzumab and contact the physician if the CMV DNA Quantitative PCR is positive.
 
Labs Before Treatment (see specific timing below):
Cycles 1 through 13, Day 1 (weekly):  CBC, CMV DNA Quantitative PCR
 
Intermittent Labs (see specific timing below):
CMV DNA Quantitative PCR every 2 weeks after treatment, for 2 months or until CD4+ count is greater than or equal to 200 cells per microliter, whichever comes later.
CD4+ count 2 months after treatment and then every 2 weeks until the CD4+ count is greater than or equal to 200 cells/microliter.
 
Ancillary - Take Home
Trimethoprim-Sulfamethoxazole DS (BACTRIM DS) Tab; QTY #54, Refill: 0  
Take 1 tablet orally three times weekly. 
Acyclovir (ZOVIRAX) 400 mg Tab; QTY #252, Refill: 0
Take 1 tablet orally twice daily. 
Allopurinol (ZYLOPRIM) 300 mg Tab; QTY #11, Refill: 0    (Beacon AOG choice)
Take 2 tablets by mouth on day 1 of first cycle, then 1 tablet by mouth daily for 9 days.  
Cetirizine (ZYRTEC) 10 mg Tab; QTY #30, Refill: 0
Take 1 tablet PO one hour prior to alemtuzumab treatment.
Acetaminophen (TYLENOL) 325 mg Tab; QTY #100, Refill: 0
Take 2 tablets PO one hour prior to alemtuzumab treatment.
 
Premedications
NOTE: If patient forgets to take acetaminophen and cetirizine from home, order acetaminophen AND either diphenhydramine OR cetirizine depending on time remaining before alemtuzumab is given.
Acetaminophen (TYLENOL) 325 mg tab. Give 2 tablets PO 30 minutes prior to alemtuzumab.
Cetirizine (ZYRTEC) 10 mg tablet. Give 1 tablet PO one hour before alemtuzumab if patient has not taken oral cetirizine from home.
DiphenhydrAMINE (BENADRYL) 50 mg in 0.9% saline 100 mL IVPB over 15 minutes. Give 30 minutes prior to alemtuzumab if patient has not taken oral cetirizine.
Antiemetics  (Level 1 - No antiemetic pre-defaulted)
 
Treatment
Reminder:  
If alemtuzumab treatment is interrupted for 7 or more days, reinitiate the titration at 3 mg or 10 mg. 
Cycle 1:
Note:  If injection is not tolerated, repeat prior dose (on a MWF schedule) and escalate when dose is tolerated. 
Day 1:  Alemtuzumab (CAMPATH) Inject 3 mg subcutaneously one time
Day 3:  Alemtuzumab (CAMPATH) Inject 10 mg subcutaneously one time
Day 5:  Alemtuzumab (CAMPATH) Inject 30 mg subcutaneously one time. 
Note: Additional dosages should be added until patient tolerates dose of 30 mg prior to starting maintenance.  
 
Cycles 2 through 13 (Maintenance):
Note:  Dose should have been escalated to 30 mg before starting maintenance (Cycle 2) 
Alemtuzumab (CAMPATH) Inject 30 mg subcutaneously on alternate days three times weekly (MWF) for 12 weeks or until complete response is obtained. 
 
PRN and HSR (Hypersensitivity Reaction) Medications
LORazepam (ATIVAN) 0.5 mg tab.  Give 1 tablet PO PRN nausea, vomiting or anxiety.  May repeat one time in 30 minutes and every 4 hours prn thereafter.
LORazepam (ATIVAN) 0.5 mg injection.  Inject 0.5 mg IV push PRN nausea, vomiting or anxiety if unable to tolerate oral formulation.  May repeat one time in 30 minutes and every 4 hours prn thereafter.
Acetaminophen (TYLENOL) 325 mg tab.  Take 2 tablets PO every 4 hours if needed for fever (greater than 100.4 F), myalgias, arthralgias or headache.
Alteplase (CATHFLO ACTIVASE) 2 mg injection.  Instill dose one time PRN into occluded central venous catheter per nursing procedure. 
Hydrocortisone (SOLU-CORTEF) 100 mg.  Give IV push one time, if needed for hypersensitivity reaction due to chemotherapy.
DiphenhydrAMINE (BENADRYL) 50 mg.  Give IV push one time, if needed for hypersensitivity reaction due to chemotherapy. 
 
Nursing
Verify that patient meets the lab parameters for administration.
Perform assessment for toxicity and tolerance.
If injection is not tolerated, repeat prior dose (on a MWF schedule) and escalate when dose is tolerated.
Infusion-related reactions, begin primary solution at wide open rate, notify MD, begin monitoring vital signs and administer PRN medications for infusion reaction. Consult MD on alemtuzumab dose to resume patientâ€™s therapy.
For any alemtuzumab dose interruption greater than or equal to 7 days, consult with MD on dose to resume patient on.
Monitor injection site.
Monitor for 60 minutes post injection until dose is stable.
Review discharge medications, instructions and future appointments.
 
References
Stilgenbauer S, et al. J Clin Oncol 27:3994-4001 
http://jco.ascopubs.org/content/27/24/3994.full.pdf+html
Hillmen P, et al. J Clin Oncol 2007;25:5616-5623 
http://jco.ascopubs.org/content/25/35/5616.full
